Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Empire Life Investments Inc.

Key Points

• Empire Life Investments Inc. increased its holdings in Regeneron Pharmaceuticals by 57.5% to a total of 6,424 shares worth approximately $4,074,000 in the first quarter.
• Several hedge funds have also boosted their positions in Regeneron, with GAMMA Investing LLC dramatically increasing its holdings by 89,825% to 815,620 shares, valued at $517,291,000.
• Regeneron Pharmaceuticals declared a quarterly dividend of $0.88 per share, representing an annualized dividend of $3.52 and a yield of 0.6%.

Empire Life Investments Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 57.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,424 shares of the biopharmaceutical company's stock after purchasing an additional 2,344 shares during the period. Empire Life Investments Inc.'s holdings in Regeneron Pharmaceuticals were worth $4,074,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 31 shares during the last quarter. Tompkins Financial Corp acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Curat Global LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $32,000. Finally, American National Bank & Trust acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $44,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. The Goldman Sachs Group dropped their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Robert W. Baird lowered their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $841.30.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $14.77 on Wednesday, reaching $555.13. 864,754 shares of the company were exchanged, compared to its average volume of 969,242. The company has a current ratio of 4.60, a quick ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a 50-day moving average of $537.05 and a 200-day moving average of $601.77. The firm has a market cap of $59.93 billion, a price-to-earnings ratio of 13.99, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $11.56 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.